MedTrace Logo

Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old

NCT01219387 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2013-01-23

No results posted yet for this study

Summary

The present study is designed to evaluate the basal serum levels of anti-mullerian hormone (AMH) and inhibin B as early predictors of ovarian response, implantation rate, and pregnancy rate in women 38 years old or older that are undergoing an IVF cycle.

Conditions

  • AMH Levels
  • Inhibin B Levels
  • IVF Patients Over 38 Years Old

Sponsors & Collaborators

  • Organon

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Reproductive Medicine Associates of New Jersey

    lead OTHER

Principal Investigators

  • Paul A Bergh, MD · Reproductive Medicine Associates of New Jersey

Eligibility

Min Age
38 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01219387 on ClinicalTrials.gov